Back to Search Start Over

Elexacaftor–Tezacaftor–Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype

Authors :
Antonella Miriam Di Lullo
Giuseppe Castaldo
Carmela Colangelo
Immacolata Zollo
Donatello Salvatore
Vito Terlizzi
Giovanni Taccetti
Marika Comegna
Felice Amato
Comegna, M.
Terlizzi, V.
Salvatore, D.
Colangelo, C.
Di Lullo, A. M.
Zollo, I.
Taccetti, G.
Castaldo, G.
Amato, F.
Source :
Antibiotics, Antibiotics, Vol 10, Iss 828, p 828 (2021), Volume 10, Issue 7
Publication Year :
2021
Publisher :
MDPI, 2021.

Abstract

The new CFTR modulator combination, elexacaftor/tezacaftor/ivacaftor (Trikafta) was approved by the FDA in October 2019 for treatment of Cystic Fibrosis in patients 6 years of age or older who have at least one F508del mutation in one allele and a minimal-function or another F508del mutation in the other allele. However, there is a group of patients, in addition to those with rare mutations, in which despite the presence of a F508del in one allele, it was not possible to identify any mutation in the other allele. To date, these patients are excluded from treatment with Trikafta in Italy, where the CF patients carrying F508del/unknown represent about 1.3% (71 patients) of the overall Italian CF patients. In this paper we show that the Trikafta treatment of nasal epithelial cells, derived from F508del/Unknown patients, results in a significant rescue of CFTR activity. Based on our findings, we think that the F508del/Unknown patients considered in this study could obtain clinical benefits from Trikafta treatment, and we strongly suggest their eligibility for this type of treatment. This study, adding further evidence in the literature, once again confirms the validity of functional studies on nasal cells in the cystic fibrosis theratyping and personalized medicine.

Details

Language :
English
ISSN :
20796382
Volume :
10
Issue :
7
Database :
OpenAIRE
Journal :
Antibiotics
Accession number :
edsair.doi.dedup.....78d9e33f688668944b62feb596932eff